about
Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancerIs there a role for IGF-1 in the development of second primary cancers?Lipid profiles and the risk of endometrial cancer in the Swedish AMORIS studyAn investigation into the relationship between statins and cancer using population-based data.Laparoscopic radical prostatectomy outcome data: how should surgeon's performance be reported? A retrospective learning curve analysis of two surgeons.Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden.Incidence of second malignancies for prostate cancerCohort Profile: the National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0.Obesity and cancer: the role of vitamin DAbility of a biomarker-based score to predict death from circulatory disease and cancer in NHANES III.Serum glucose and fructosamine in relation to risk of cancerCalcium intake and serum concentration in relation to risk of cardiovascular death in NHANES III.Inorganic phosphate and the risk of cancer in the Swedish AMORIS studyAssociation between levels of C-reactive protein and leukocytes and cancer: three repeated measurements in the Swedish AMORIS studySerum calcium and risk of gastrointestinal cancer in the Swedish AMORIS studyMortality following hip fracture in men with prostate cancer.Serum glucose and risk of cancer: a meta-analysis.Comparison of three magnetic nanoparticle tracers for sentinel lymph node biopsy in an in vivo porcine modelQuantifying the evidence for the risk of metabolic syndrome and its components following androgen deprivation therapy for prostate cancer: a meta-analysis.Prediagnostic serum glucose and lipids in relation to survival in breast cancer patients: a competing risk analysis.How to model temporal changes in comorbidity for cancer patients using prospective cohort dataCohort Profile Update: The National Prostate Cancer Register of Sweden and Prostate Cancer data Base--a refined prostate cancer trajectory.Metabolic serum biomarkers for the prediction of cancer: a follow-up of the studies conducted in the Swedish AMORIS studyThe association between circulating IGF1, IGFBP3, and calcium: results from NHANES III.Associations of C-Reactive Protein, Granulocytes and Granulocyte-to-Lymphocyte Ratio with Mortality from Breast Cancer in Non-Institutionalized American Women.Investigating the association between allergen-specific immunoglobulin E, cancer risk and survival.Serum Lipids and the Risk of Gastrointestinal Malignancies in the Swedish AMORIS StudyGlucose and lipoprotein biomarkers and breast cancer severity using data from the Swedish AMORIS cohort.Gamma-glutamyl transferase and C-reactive protein as alternative markers of metabolic abnormalities and their associated comorbidites: a prospective cohort study.Serum leptin, C-reactive protein, and cancer mortality in the NHANES IIIProgression of breast cancer following locoregional ipsilateral recurrence: importance of interval time.Serum lipid profiles and cancer risk in the context of obesity: four meta-analyses.Serum lactate dehydrogenase and survival following cancer diagnosis.Causes of death in men with localized prostate cancer: a nationwide, population-based study.Family history of breast cancer and its association with disease severity and mortalityIron metabolism and risk of cancer in the Swedish AMORIS study.Association between baseline serum glucose, triglycerides and total cholesterol, and prostate cancer risk categoriesProstate-specific antigen testing in inner London general practices: are those at higher risk most likely to get tested?Global incidence and outcome of testicular cancer.Serum Calcium and the Risk of Breast Cancer: Findings from the Swedish AMORIS Study and a Meta-Analysis of Prospective Studies.
P50
Q24186145-D89F5AF1-5A73-4336-8201-944FEB18C7C2Q28069262-E927515A-240B-4508-833F-446BCB9D11D4Q28385524-BB3CAA08-2CB9-4D98-9CBB-111E9C122BEFQ30851261-24CA44D3-30E3-449D-B401-DE8488E913BFQ31123730-78D74443-C3B0-4ADC-B826-5DC8D3770266Q33819138-E6B4FF70-E074-4C78-88CC-17296CD49F12Q33927733-63A973AC-EC67-4812-BE9A-33D5E2F0C4D2Q34259095-16011D39-A871-44BA-8897-498FA4937FA5Q34278744-05171C2A-BAD4-43B2-8482-7733CBB72B8CQ34455636-54881351-A4E1-449F-912B-E276562A9A46Q34571468-52947C10-07AE-4F18-B333-1C6B40BFC6B2Q34674507-AC4B52A1-D68C-49F8-942D-6D42384C3500Q34739712-F72F80D6-44DD-4089-8A66-D771019E0D88Q34806349-F36988E8-1FA5-4DE3-8F95-018455BECB31Q34833951-4C817171-6E86-4F95-9949-8B0DEE7DD061Q35005045-19BDF89D-2973-4274-A051-B4BA734AD375Q35059999-768FA098-FA69-4634-B43A-3DB2C7BBA3BEQ35101000-4191B14D-2538-445D-94BB-E33848165D12Q35202889-F5256078-3466-4D7C-B7EA-246CCF0BF4DDQ35844236-1BA4EF15-C58C-426E-A756-AF4E23834ADEQ35845867-0A426B89-6832-49AA-88CF-53563440F20AQ35867402-825CC883-E7E4-4A59-BF03-F53D629ED278Q35935362-50B980B1-5C5C-4BD2-8B2F-FD6923C98406Q35990291-FDE40802-1EE9-4410-ABF1-142275B8B142Q36050289-26142C9A-464E-4137-A8BC-AEE8323316F2Q36089397-ED30FFD1-DD69-40E5-9F60-E223D17B5F90Q36219627-452C8E71-239E-4DA9-93D1-6780FA9F4380Q36334462-C28421A6-D657-4DC2-BC75-34B419050256Q36429561-BA3A5EC3-2AF1-42B9-9B8E-339D0BFC1BEDQ36451590-2DCC0C32-0A86-499B-99C6-AC371C41959EQ36472953-A78CE49F-EA41-452C-A1FD-FCB9ABF8B630Q36584255-A8F52758-41D9-4A81-AE3C-55E2EE3D6402Q36750612-84D98451-5188-41D0-AAFF-6C0AFBCE1A93Q36799921-A19CFC74-4020-4CF5-A8DC-FA8A735F9DCBQ36895125-F23F7CD7-6088-4DE2-AC71-DF39AE626C9BQ36909373-668DCDA6-B5EE-42B8-A42E-50AC7DA516A7Q37045608-E17518AF-845D-4292-BD39-BF3249EB7F81Q37100980-75F51DFF-8A59-457C-BCA6-39F255A410C4Q37245541-F49120F7-A485-4DC8-ACC9-0EB7C2A99184Q37286483-4B5F3F77-4D8A-42A7-A69F-37C5B4896502
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mieke Van Hemelrijck
@ast
Mieke Van Hemelrijck
@en
Mieke Van Hemelrijck
@es
Mieke Van Hemelrijck
@nl
Mieke Van Hemelrijck
@sl
type
label
Mieke Van Hemelrijck
@ast
Mieke Van Hemelrijck
@en
Mieke Van Hemelrijck
@es
Mieke Van Hemelrijck
@nl
Mieke Van Hemelrijck
@sl
prefLabel
Mieke Van Hemelrijck
@ast
Mieke Van Hemelrijck
@en
Mieke Van Hemelrijck
@es
Mieke Van Hemelrijck
@nl
Mieke Van Hemelrijck
@sl
P106
P1153
25932351400
P21
P31
P496
0000-0002-7317-0858